 |
| 344. |
Gerson L, Triadafilopoulos G, Sahbaie P, Young W, Sloan S, Robinson M, Miner PB Jr and Gardner JD Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors. BMC Gastroenterology 8:15-26, 2008 |
| 343. |
Gardner JD, Young W, Sloan S, Robinson M, Miner PB Jr. The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings. Aliment Pharmacol Ther 23:629-638, 2006. |
| 342. |
Gardner JD, Young W, Sloan S, Robinson M, Miner PB Jr. The fractal nature of human gastro-oesophageal disease. Aliment Pharmacol Ther 22:823-830, 2005.
|
| 341. |
Gardner JD, Sloan S, Robinson M, Miner PB. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor. Aliment Pharmacol Ther 20:1381-1386, 2004. |
| 340. |
Gardner JD, Sloan S, Robinson M, Miner PB. Oesophageal pH has a power-law distribution in control and gastro-oesophageal reflux disease subjects. Aliment Pharmacol Ther 20:1373-1379, 2004. |
| 339. |
Gardner JD, Gallo-Torres H, Sloan S, Robinson M, Miner PB Jr. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 18:891-905, 2003. |
| 338. |
Gardner JD, Sloan S, Robinson M, Miner PB Jr. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux patients treated with a proton pump inhibitor. Aliment Pharmacol Ther 18:133-140, 2003. |
| 337. |
Gardner, J.D., Sloan, S., Miner, P.B. Jr., Robinson, M. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastroesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 17:954-964, 2003. |
| 336. |
Gardner, J.D., Sloan, S., Miner, P.B. Jr., Robinson, M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastroesophageal reflux disease. Aliment Pharmacol Ther 17:945-953, 2003. |
| 335. |
Gardner, J.D., Rodriguez-Stanley, S., Robinson, M., Miner, P.B. Jr. Cisapride inhibits meal-stimulated gastric acid secretion and postprandial gastric acidity in subjects with gastroesophageal reflux disease. Aliment Pharmacol Ther 16:1819-1829, 2002. |
| 334. |
Gardner, J.D., Ciociola, A.A., Robinson, M, McIsaac, R.L. Determination of the time of onset of action of ranitidine and famotidine on gastric acidity. Aliment Pharmacol Ther 16:1-11, 2002. |
| 333. |
Gardner, J.D., Ciociola, A.A., Robinson, M. Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. J. Appl. Physiol. 92: 427-434, 2002 |
| 332. |
Robinson, M., Rodriguez-Stanley, S., Ciociola, A.A., Filinto, J., Zubaidi, S, Miner, P.B. Jr., Gardner, J.D. Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. Dig. Dis. Sci. 47: 265-273, 2002. |
| 331. |
Gardner, J.D., Perdomo, C., Sloan, S., Hahne, W.F., Barth, J.A., Rodriguez-Stanley, S., and Robinson, M. Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol. Ther. 16: 455-464,2002. |
| 330. |
Gardner, J.D., Rodriguez-Stanley, S., and Robinson, M. Integrated acidity and the pathophysiology of GERD. Am. J. Gastroenterol. 96: 1363-1370, 2001. |
| 329. |
Robinson, M., Rodriguez-Stanley, S., Ciociola, A.A., Filinto, J., Zubaidi, S, Miner, P..B. Jr., Gardner, J.D. Synergy between low dose ranitidine and antacid in reducing gastric and esophageal acidity and relieving meal-induced heartburn. Aliment. Pharmacol. Ther. 15: 1365-1374, 2001. |
| 328. |
Joshi, S. N. and Gardner, J.D. Gastrin and colon cancer: A unifying hypothesis. Dig, Dis. 14: 334-344, 1996. |
| 327. |
Bastani, B., Yang, L., Baldassare, J.J., Pollo, D.A. and Gardner, J.D. Cellular distributions of isoforms of protein kinase C (PKC) in pancreatic acini. Biochim. Biophys. Acta. 1269: 307-315, 1995. |
| 326. |
Huang, S-C., Talkad, V.D., Fortune, K.P., Jonnalagadda, S., Severi, C., Delle Fave, G. and Gardner, J.D. Modulation of cholecystokinin activity by albumin. Proc. Natl. Acad. Sci. USA. 92: 10312-10316, 1995. |
| 325. |
Huang, S-C., Fortune, K.P., Wank, S.A., Kopin, A.S. and Gardner, J.D. Multiple affinity states of different cholecystokinin (CCK) receptors. J. Biol. Chem. 269: 26121-26126, 1994 |
| 324. |
Pollo, D.A., Baldassare, J.J., Honda, T., Henderson, P.A., Talkad, V.D. and Gardner, J.D. Effects of cholecystokinin (CCK) and other secretagogues on isoforms of protein kinase C (PKC) in pancreatic acini. Biochim. Biophys. Acta. 1224: 127-138, 1994. |
| 323. |
Pandya, P.K., Huang, S-C., Talkad, V.D., Wank, S.A. and Gardner, J.D. Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Biochim. Biophys. Acta. 1224: 117-126, 1994 |
| 322. |
Talkad, V.D., Patto, R.J., Metz, D.C., Turner, R.J., Fortune, K.P., Bhat, S.T. and Gardner, J.D. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Biochim. Biophys. Acta. 1224: 103-116, 1994. |
| 321. |
Talkad, V.D., Fortune, K.P., Pollo, D.A., Shah, G.N., Wank, S.A. and Gardner, J.D. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc. Natl. Acad. Sci. USA. 91: 1868-1872, 1994. |
| 320. |
Metz, D.C., Pradhan, T.K., Mrozinski, J.E., Jr., Jensen, R.T., Turner, R.J., Patto, R.J. and Gardner, J.D. Effect of inhibition of microsomal Ca2+-ATPase on cytoplasmic calcium and enzyme secretion in pancreatic acini. Biochim. Biophys. Acta. 1220: 199-208, 1994. |
|
 |
|
|
